Fig. 4: The epitope specificity of neutralizing antibodies from MARV and RAVV mRNA vaccine recipients differ. | Nature Communications

Fig. 4: The epitope specificity of neutralizing antibodies from MARV and RAVV mRNA vaccine recipients differ.

From: Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses

Fig. 4

Neutralizing activity of day 54 (A) MARV (green) or (B) RAVV (blue) mRNA vaccine immune sera (n = 5 per vaccine) pre-absorbed with GPΔmuc (circle outline) and GPcl (solid square) or GPΔmucΔw (solid triangle, RAVV only) expressed as a percentage relative to the neutralizing activity of the same sera without pre-adsorption. Sera from MARV or RAVV vaccinated groups, diluted to achieve 80% of their neutralization activity, were incubated with increasing concentrations of truncated GPs from the relevant virus. The percentage of restoration of infectivity is plotted against concentration of competing GP. Data points denote group means ± SEM. Curves were fit using the least-squares fit method of non-linear regression analysis. Extra sum-of-squares F test was performed to determine significant differences in best-fit parameters between GPΔmuc and GPcl curves: (A) p  <  0.0001; F(4,52)  =  11.45 (B), p = 0.0402; F(4,62) =  2.671.

Back to article page